Novo’s $1.4 Billion Orbis Deal Does Not Say What It Paid at Signing
- Orbis Medicines and Novo Nordisk announced a strategic collaboration and licence agreement on 17 September 2026 to discover oral macrocycle therapeutics for cardiometabolic targets. Orbis is eligible for up to $1.4 billion in upfront and potential development and commercial milestone payments, plus tiered royalties.
- The release does not separate the upfront from the milestones. It states the total as a single figure covering both. Novo will also make a strategic investment in Orbis, with no amount disclosed.
- The platform is nGen, a lab-in-the-loop system combining generative AI with high-throughput synthesis to design, synthesise and analyse thousands of synthetic macrocycles, called nCycles, in weeks. Orbis states its pipeline is initially focused on targets validated by blockbuster biologics delivered by injection.
- Orbis has raised EUR 116 million to date, including a EUR 90 million Series A led by NEA with Lilly Ventures, Cormorant, EIFO, Forbion and Novo Holdings. Its board chair is Mikael Dolsten, formerly chief scientific officer and president of R&D at Pfizer.
Deal read
The headline has no denominator. Upfront and milestones are stated as one number, which makes the commitment impossible to assess from outside the negotiation.
- A same-day comparison shows the alternative. Dualitas disclosed $36.5 million upfront against a $1 billion total with Roche, roughly 3.65%, on the same date. Hanmi separated $190 million from $2.3 billion with Genentech in August. Orbis and Novo chose not to, and that choice is itself information.
- Novo Holdings was already on the cap table before Novo signed. The investment arm participated in the EUR 90 million Series A, and the operating company has now added a discovery deal plus a second strategic investment. Watching the venture arm is a reliable leading indicator of where the parent partners next.
- Lilly Ventures is an investor in the platform Novo just licensed. Orbis carries both on its register, and the collaboration targets cardiometabolic disease, where the 2 companies compete most directly. Whatever Orbis discovers outside this agreement sits inside a cap table with a competitor on it.